Skip To Main Content
E. Barr on Muck Rack

E. Barr

As seen in: Color Research & Application, MENAFN
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with E.

Contact E., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Readers' Favorite Recognizes“Skellig” By E. R. Barr In Its Annual International Book Award Contest

|
By E. Barr
| MENAFN
Readers' Favorite Recognizes“Skellig” By E. R. Barr In Its Annual International Book Award Contest 2025-10-20 03:04:39 (MENAFN- GetNews) Readers' Favorite recognizes "Skellig" by E. R. Barr in its annual international book award contest, currently available at . The Readers' Favorite International Book Award Contest featured thousands of contestants from over a dozen countries, ranging from new independent authors to NYT best-sellers and celebrities.
Open in Who Shared Issue with article?

Origins of great scientists

|
By E. Barr
| physicstoday.scitation.org
Article Metrics Altmetric Please Note: The number of views represents the full text views from December 2016 to date. Article views prior to December 2016 are not included.
Open in Who Shared View Duplicates (32) Issue with article?

Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with HCV genotype 2, 4, 5, or 6 infection: the C-SCAPE study

|
By A. K. Brown, A. Zekry, S. K. Roberts, B. Zhang, M. N. Robertson, E. Barr, E. Zuckerman, G. R. Foster, F. Lahser, C. Durkan, C. Badshah, J. Wahl, B. Haber
| Color Research & Application Verified
People with hepatitis C virus (HCV) infection other than genotype 1 represent a heterogeneous group. The aim of the phase 2 C-SCAPE study was to evaluate elbasvir/grazoprevir (EBR/GZR), with or without ribavirin (RBV), in participants with HCV genotype 2, 4, 5 or 6 infection. This was a part randomized, open-label, parallel-group study (NCT01932762; PN047-03) of treatment-naive, non-cirrhotic participants.
Open in Who Shared Issue with article?
See all 4 articles